Varices progression/In HCV and advanced fibrosis

Saturday, October 9, 2010

Varices progression/In HCV and advanced fibrosis

It was very interesting what the study found, one finding was that people with bridging fibrosis should be checked for Varices.

Click To Listen To The Podcast From Gastroenterolgy

This study was a substudy of the

Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial

June 2010

l

l

Development and progression of gastroesophageal varices in patients with chronic hepatitis C.

A study in the June 2010 issue of Gastroenterology sought to identify the incidence and predictors of de novo gastroesophageal variceal formation and progression in a large cohort of patients with chronic hepatitis C and advanced fibrosis. Dr. Kuemmerle speaks with the author of this article, Dr. Robert J. Fontana of the Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School.
Fontana RJ, Sanyal AJ, Ghany MG, et al. Factors that Determine the Development and Progression of Gastroesophageal Varices in Patients with Chronic Hepatitis C. Gastroenterology 2010; June; 138(7): 2321-2331.

http://www.gastro.org/

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.